Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Tina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101633-101633
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 127
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Philip N. Newsome, Phil Ambery
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1557-1565
Open Access | Times Cited: 75
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 71
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 162-173
Closed Access | Times Cited: 71
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 61
Obesity and diabetes
Chrysoula Boutari, Antea DeMarsilis, Christos S. Mantzoros
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110773-110773
Closed Access | Times Cited: 57
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher, Julio Rosenstock, Josef Hoefler, et al.
Diabetologia (2023) Vol. 67, Iss. 3, pp. 470-482
Open Access | Times Cited: 56
GLP-1-directed NMDA receptor antagonism for obesity treatment
Jonas Petersen, Mette Q. Ludwig, Vaida Juozaityte, et al.
Nature (2024) Vol. 629, Iss. 8014, pp. 1133-1141
Open Access | Times Cited: 38
Diabetes mellitus—Progress and opportunities in the evolving epidemic
E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3789-3820
Closed Access | Times Cited: 33
MASH clinical trials and drugs pipeline: An impending tsunami
Mazen Noureddin
Hepatology (2024)
Closed Access | Times Cited: 17
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Moody Al Roomy, Kainat Hussain, Hawraa M. Behbehani, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 17
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906
Arvid Jungnik, Jorge Arrubla, Leona Plum‐Mörschel, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 1011-1023
Open Access | Times Cited: 46
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 36
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
Eric Lawitz, Mandy Fraessdorf, Guy Neff, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. 837-846
Open Access | Times Cited: 14
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 8
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Jiahua Zhang, Jintao Wei, Weiwen Lai, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1651-1651
Open Access | Times Cited: 1
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity
Rie Yazawa, Masahiro Ishida, Yesilda Balavarca, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1973-1984
Open Access | Times Cited: 17
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Leo Thomas, Eric Martel, Wolfgang Rist, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2368-2378
Open Access | Times Cited: 5
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son, Soo Lim
Endocrinology and Metabolism (2024) Vol. 39, Iss. 2, pp. 206-221
Open Access | Times Cited: 5
Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice
Osamu Kikuchi, Yuichi Ikeuchi, Masaki Kobayashi, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 9, pp. 1177-1190
Open Access | Times Cited: 5
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 5, pp. 445-460
Open Access | Times Cited: 5
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano, Raffaele Galiero, Maria Rocco, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2039-2039
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top